Compare VRAX & MBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRAX | MBOT |
|---|---|---|
| Founded | 2013 | 2010 |
| Country | United Kingdom | United States |
| Employees | 26 | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3M | 126.9M |
| IPO Year | 2021 | 2000 |
| Metric | VRAX | MBOT |
|---|---|---|
| Price | $2.86 | $1.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $1.00 | ★ $7.50 |
| AVG Volume (30 Days) | 199.1K | ★ 545.7K |
| Earning Date | 06-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.27 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $116,887.00 |
| Revenue This Year | $217,274.83 | N/A |
| Revenue Next Year | N/A | $119.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.10 | $1.60 |
| 52 Week High | $13.19 | $4.62 |
| Indicator | VRAX | MBOT |
|---|---|---|
| Relative Strength Index (RSI) | 49.88 | 35.87 |
| Support Level | $0.19 | N/A |
| Resistance Level | $3.10 | $2.21 |
| Average True Range (ATR) | 0.20 | 0.10 |
| MACD | -0.09 | -0.02 |
| Stochastic Oscillator | 54.67 | 3.49 |
Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.
Microbot Medical Inc is a medical device company specializing in the research, design, and development of next-generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, the company has developed the LIBERTY Endovascular Robotic Surgical System, a fully disposable robot for various endovascular interventional procedures. The company has a single operating and reportable segment, which is the development of robotic devices for endoluminal surgery.